Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature

Lung Cancer

Volumn 75, Issue 3, 2012, Pages 391-397

  Ter Heine, R ^a   Van Den Bosch, R T A ^a   Schaefer Prokop, C M ^a   Lankheet, N A G ^b   Beijnen, J H ^b   Staaks, G H A ^a   Van Der Westerlaken, M M ^a   Malingre M M ^a   Van Den Brand, J J G ^a  

^a MEANDER MEDICAL CENTER   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

EGFR; Erlotinib; Interstitial lung disease; Pharmacology; Toxicity

Indexed keywords

C REACTIVE PROTEIN; ERLOTINIB; OXYGEN; PREDNISOLONE;

AGED; ANGINA PECTORIS; ARTERIAL GAS; ARTICLE; CANCER CHEMOTHERAPY; CANCER SIZE; CASE REPORT; CAUCASIAN; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DYSPNEA; FOLLOW UP; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; HYPOXIA; INTERSTITIAL LUNG DISEASE; LEUKOCYTE COUNT; LIQUID CHROMATOGRAPHY; LUNG NON SMALL CELL CANCER; MALE; MEDICAL HISTORY; OXYGEN THERAPY; PALLIATIVE THERAPY; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESPIRATORY FAILURE; SPUTUM ANALYSIS; TANDEM MASS SPECTROMETRY; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FATAL OUTCOME; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MYOCARDIAL INFARCTION; PLEURAL NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 84856566959     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.10.008     Document Type: Article

References (32)

1. Hotta K., Kiura K., Takigawa N., Yoshioka H., Harita S., Kuyama S., et al. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience. J Thorac Oncol 2010, 5(2):179-184.
2. Copley S.J., Wells A.U., Hawtin K.E., Gibson D.J., Hodson J.M., Jacques A.E., et al. Lung morphology in the elderly: comparative CT study of subjects over 75 years old versus those under 55 years old. Radiology 2009, 251(2):566-573.
3. Hidalgo M., Siu L.L., Nemunaitis J., Rizzo J., Hammond L.A., Takimoto C., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001, 19(13):3267-3279.
4. Bach J.P., Kiessling A.M., Kleinhans A., Faoro C., Gorg C., Riera-Knorrenschild J., et al. Pulmonary fibrosis in a patient treated with erlotinib. Onkologie 2006, 29(7):342-343.
5. Chou C.L., Ko H.W., Wang C.W., Yu C.T., Kuo H.P., Huang C.D. Erlotinib-associated near-fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma. Chang Gung Med J 2010, 33(1):100-105.
6. Del Castillo Y., Espinosa P., Bodi F., Alcega R., Munoz E., Rabasso C., et al. Interstitial lung disease associated to erlotinib treatment: a case report. Cases J 2010, 3:59.
7. Hsieh C.H., Chang H.T., Lin S.C., Chen Y.J., Wang L.Y., Hsieh Y.P., et al. Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment-case report. BMC Cancer 2010, 10:696.
8. Lind J.S., Smit E.F., Grunberg K., Senan S., Lagerwaard F.J. Fatal interstitial lung disease after erlotinib for non-small cell lung cancer. J Thorac Oncol 2008, 3(9):1050-1053.
9. Liu V., White D.A., Zakowski M.F., Travis W., Kris M.G., Ginsberg M.S., et al. Pulmonary toxicity associated with erlotinib. Chest 2007, 132(3):1042-1044.
10. Makris D., Scherpereel A., Copin M.C., Colin G., Brun L., Lafitte J.J., et al. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer 2007, 7:150.
11. Nasrallah H., Bar-Sela G., Haim N. Fatal interstitial lung disease associated with gemcitabine and erlotinib therapy for lung cancer. Med Oncol 2011.
12. Park S.D., Kim A., Park J.S., Shin C.H., Nam H.S., Kim L., et al. Recurrent erlotinib-induced interstitial lung disease on non-small cell lung cancer. Tuber Respir Dis 2005, 67(5):445-448.
13. Tammaro K.A., Baldwin P.D., Lundberg A.S. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa). J Oncol Pharm Pract 2005, 11(3):127-130.
14. Togashi Y., Masago K., Mishima M., Fukudo M., Inui K. A case of radiation recall pneumonitis induced by erlotinib, which can be related to high plasma concentration. J Thorac Oncol 2010, 5(6):924-925.
15. Toh C.K., Lee P., Chowbay B., Goh J.W., Mancer K., Tan P.H. An inflammatory response with worsening of pleural effusion on treatment with erlotinib in non-small cell lung cancer. Acta Oncol 2007, 46(2):256-258.
16. Um S.J., Lee S.K., Yang D.K., Son C., Roh M.S., Kim K.N., et al. Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis. Clin Respir J 2009, 3(3):181-184.
17. Vahid B., Esmaili A. Erlotinib-associated acute pneumonitis: report of two cases. Can Respir J 2007, 14(3):167-170.
18. Yoneda K.Y., Shelton D.K., Beckett L.A., Gandara D.R. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. J Thorac Oncol 2007, 2(6):537-543.
19. Ando M., Okamoto I., Yamamoto N., Takeda K., Tamura K., Seto T., et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006, 24(16):2549-2556.
20. Takano T., Ohe Y., Kusumoto M., Tateishi U., Yamamoto S., Nokihara H., et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004, 45(1):93-104.
21. Kudoh S., Kato H., Nishiwaki Y., Fukuoka M., Nakata K., Ichinose Y., et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008, 177(12):1348-1357.
22. Oh I., Choi S., Kwon Y.S., Kim K.S., Kim Y.I., Lim S.C., et al. Clinical characteristics of EGFR-TKI-induced interstitial pneumonitis in Korean non-small-cell lung cancer patients. Clin Lung Cancer 2009, 10(5.). [Ref Type: Abstract].
23. Higenbottam T., Kuwano K., Nemery B., Fujita Y. Understanding the mechanisms of drug-associated interstitial lung disease. Br J Cancer 2004, 91(Suppl. 2):S31-S37.
24. Piguet P.F. Cytokines involved in pulmonary fibrosis. Int Rev Exp Pathol 1993, 34(Pt B):173-181.
25. Aida S., Tamai S., Sekiguchi S., Shimizu N. Distribution of epidermal growth factor and epidermal growth factor receptor in human lung: immunohistochemical and immunoelectron-microscopic studies. Respiration 1994, 61(3):161-166.
26. Li X., Kamenecka T.M., Cameron M.D. Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities. Chem Res Toxicol 2009, 22(10):1736-1742.
27. Li X., Kamenecka T.M., Cameron M.D. Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile. Drug Metab Dispos 2010, 38(7):1238-1245.
28. Harada C., Kawaguchi T., Ogata-Suetsugu S., Yamada M., Hamada N., Maeyama T., et al. EGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium. Am J Respir Crit Care Med 2011, 183(6):743-751.
29. Rudin C.M., Liu W., Desai A., Karrison T., Jiang X., Janisch L., et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 2008, 26(7):1119-1127.
30. Thomas F., Rochaix P., White-Koning M., Hennebelle I., Sarini J., Benlyazid A., et al. Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. Eur J Cancer 2009, 45(13):2316-2323.
31. Jansman F.G., Reyners A.K., van Roon E.N., Smorenburg C.H., Helgason H.H., le C.M., et al. Consensus-based evaluation of clinical significance and management of anticancer drug interactions. Clin Ther 2011, 33(3):305-314.
32. Kletzl H., Zwanziger E., Kirkpatrick C., Luedin E. Effect of ciprofloxacin on the systemic exposure to erlotinib. J Clin Oncol 2011, 26(Suppl. 15):19047.